Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-powered CDI, coding, and utilization management platform improving revenue accuracy for health systems; raised $80M+. Austin TX; Artifact uses ML trained on millions of clinical encounters to predict documentation gaps and prioritize physician query opportunities for inpatient coding teams.
Iodine Software is an AI health IT company that specializes in clinical documentation integrity (CDI), medical coding, and utilization management for inpatient and outpatient care settings. Founded in 2010 and headquartered in Austin, Texas, Iodine has raised more than $80 million and serves dozens of health systems representing hundreds of hospitals across the United States. The company's flagship product, Artifact, uses machine learning trained on millions of clinical encounters to predict documentation gaps, suggest appropriate diagnosis codes, and prioritize physician query opportunities in real time as patients receive care.\n\nIodine's approach is distinguished by the depth of its AI models, which are trained on a proprietary dataset of clinical notes, lab values, and billing outcomes. This allows Artifact to identify clinically significant conditions that may be present but undocumented — such as malnutrition, sepsis, or respiratory failure — and surface targeted queries to CDI specialists and physicians before documentation windows close. The platform integrates with major inpatient EHRs including Epic and Oracle Cerner, embedding intelligence directly into CDI and coding workflows.\n\nBeyond CDI, Iodine has expanded into utilization management and care progression analytics, helping hospitals identify patients who may be inappropriately placed in observation status versus inpatient, reduce length of stay outliers, and defend against payer audits. The company competes with 3M Health Information Management, Optum, and a growing number of AI-native CDI vendors, and has established itself as a trusted partner for health systems seeking to improve documentation accuracy and revenue cycle integrity.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.